A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients

International Journal of Cancer

Volumn 135, Issue 2, 2014, Pages 379-390

  D'Alterio, Crescenzo ^a   Avallone, Antonio ^a   Tatangelo, Fabiana ^a   Delrio, Paolo ^a   Pecori, Biagio ^a   Cella, Laura ^b   Pelella, Alessia ^a   D'Armiento, Francesco Paolo ^c   Carlomagno, Chiara ^c   Bianco, Franco ^a   Silvestro, Lucrezia ^a   Pacelli, Roberto ^b,c   Napolitano, Maria ^a   Iaffaioli, Rosario Vincenzo ^a   Scala, Stefania ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

CXCR4; outcome; predictive model; preoperative radio chemotherapy; rectal cancer

Indexed keywords

CAPECITABINE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; RALTITREXED; STROMAL CELL DERIVED FACTOR 1;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECTUM CANCER; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR;

CXCR4; OUTCOME; PREDICTIVE MODEL; PREOPERATIVE RADIO CHEMOTHERAPY; RECTAL CANCER;

AGED; AREA UNDER CURVE; CHEMOKINE CXCL12; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIATION TOLERANCE; RECEPTORS, CXCR; RECEPTORS, CXCR4; RECTAL NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84900028451     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28689     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40.
3. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004; 22: 1785-96.
4. Avallone A, Delrio P, Lastoria S, et al. Chemo-radiotherapy in locally advanced rectal cancer: what is the optimal strategy? Eur J Cancer Suppl 2008; 6: 70-73.
5. Bujko K, Glynne-Jones R, Bujko M,. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy?. A systematic review of randomised trials. Ann Oncol 2010; 21: 1743-50.
6. Avallone A, Aloj L, Delrio P, et al. Multidisciplinary approach to rectal cancer: are we ready for selective treatment strategies? Anticancer Agents Med Chem 2013; 13: 852-60.
7. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-96.
8. Bujko K, Michalski W, Kepka L, et al. Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys 2007; 67: 369-77.
9. Fietkau R, Barten M, Klautke G, et al. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis Colon Rectum 2006; 49: 1284-92.
10. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835-44.
11. Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, #distant |metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 2011; 29: 3163-72.
12. Kim J, Mori T, Chen SL, et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 2006; 244: 113-20.
13. Ottaiano A, Franco R, Talamanca A, et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 2006; 12: 2795-803.
14. Zhang SS, Han ZP, Jing YY, et al. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med 2012; 10: 85.
15. Saigusa S, Toiyama Y, Tanaka K, et al. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. Ann Surg Oncol 2010; 17: 2051-8.
16. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-48.
17. Ingold B, Schulz S, Budczies J, et al. The role of vascular CXCR4 expression in colorectal carcinoma. Histopathology 2009; 55: 576-86.
18. Brand S, Dambacher J, Beigel F, et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res 2005; 310: 117-30.
19. Thelen M, Thelen S,. CXCR7, CXCR4 and CXCL12: an eccentric trio? J Neuroimmunol 2008; 198: 9-13.
20. Miao Z, Luker KE, Summers BC, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA 2007; 104: 15735-40.
21. D'Alterio C, Consales C, Polimeno M, et al. Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets 2010; 10: 772-81.
22. Xu H, Wu Q, Dang S, et al. Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. PLoS One 2011; 6: e27399.
23. Avallone A, Delrio P, Pecori B, et al. Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome. Int J Radiat Oncol Biol Phys 2011; 79: 670-6.
24. Avallone A, Di Gennaro E, Delrio P, et al. Neoadjuvant multidisciplinary phase II study (BRANCH) of an early bevacizumab schedule plus chemo-radiation therapy in rectal cancer: efficacy, safety, and biomarkers. AACR meeting, 2012, abstract LB219.
25. Akishima-Fukasawa Y, Nakanishi Y, Ino Y, et al. Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. Am J Clin Pathol 2009; 132: 202-10.
26. Pacelli R, Conson M, Cella L, et al. Radiation therapy following surgery for localized breast cancer:outcome prediction by classical prognostic factors and approximated genetic subtypes. J Rad Res 2013; 54: 292-8.
27. El Naqa I, Bradley J, Blanco AI, et al. Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors. Int J Radiat Oncol Biol Phys 2006; 64: 1275-86.
28. Hernandez L, Magalhaes MA, Coniglio SJ, et al. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res 2011; 13: R128.
29. Carlomagno C,. Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol 2009; 20: 906-12.
30. Drury LJ, Ziarek JJ, Gravel S, et al. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc Natl Acad Sci USA 2011; 108: 17655-60.
31. Heinrich EL, Lee W, Lu J, et al. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J Transl Med 2012; 10: 68.
32. Hiller DJ, Li BD, Chu QD,. CXCR4 as a predictive marker for locally advanced breast cancer post-neoadjuvant therapy. J Surg Res 2011; 166: 14-18.
33. Margolin DA, Silinsky J, Grimes C, et al. Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1α/CXCR4 paracrine signaling. Neoplasia 2011; 13: 874-86.
34. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011; 29: 11-16.
35. Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012; 30: 1620-27.
36. Willett CG, Duda DG, Ancukiewicz M, et al. A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist 2010; 15: 845-51.
37. Hiratsuka S, Duda DG, Huang Y, et al. C-X-C receptor type4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc Natl Acad Sci USA. 2011; 108: 302-7.
38. Xu L, Duda DG, di Tomaso E, et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009; 69: 7905-10.
39. De Clercq E,. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009; 77: 1655-64.